ClinicalTrials.gg
CompletedNCT02598570Updated Feb 6, 2017

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

A Phase 1 interventional study of duvelisib in Lymphoma, sponsored by AbbVie. Completed at 3 sites in Japan. Open to participants aged 20 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-02-06.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
20 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Lymphoma by AbbVie — none open to participants now, none under way, none of them phase 3. Lymphoma · AbbVie.

Enrollment
12th of 14
7 · median 35
Started
2015
the only one that year
Phase 1
5 of 15
none open now
Registered
13th of 15
by date

Among the 15 studies in Lymphoma by AbbVie, this one is the 12th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 1, and was the 13th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

None of the 15 studies in Lymphoma by AbbVie is open now. The open studies under Lymphoma, anywhere →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Lymphoma by AbbVie as a file.
02

Study summary

This study seeks to evaluate the safety and pharmacokinetics of duvelisib in Japanese participants with relapsed or refractory lymphoma.

03

Conditions studied

  • Lymphoma

Browse trials for

Keywords

  • Relapsed Lymphoma
  • Phosphoinositide 3-kinase (PI3K) Inhibitor
  • Duvelisib
  • Japanese
  • Refractory Lymphoma
04

Who can participate

Ages eligible
20 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of lymphoma (excluding lymphoblastic lymphoma)
  • Progressed during, to, intolerant of, or ineligible for established therapy, or has a disease for which there is no established therapy
  • (ECOG) performance status lower than or equal to 2
  • of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Any prior treatment with a PI3K inhibitor or Bruton's tyrosine kinase (BTK) inhibitor
  • Ongoing treatment with chronic immune-suppressants
  • Overt CNS lymphoma
  • Inadequate hepatic, bone marrow, or renal function
  • History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
  • Venous thromboembolic event requiring anticoagulation
  • Presence of active systemic infection within 72 hours of treatment
  • (HIV) infection
  • Pregnant or lactating women
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    duvelisib

    Duvelisib will be administered orally as a fixed dose in 28-day cycles.

    Drug: duvelisib

Interventions

  • Duvelisib will be administered orally as a fixed dose in 28-day cycles.

    Also known as: IPI-145, ABBV-954

06

What researchers measure

Primary outcomes

  1. Number of participants reporting Treatment-emergent Adverse Events

    The number of participants reporting treatment-emergent adverse events.

    Time frame: Throughout the study for approximately 2 years

  2. Maximum Observed Plasma Concentration (Cmax) of Duvelisib

    Time frame: Cycle 1 Day 1, 8, 15, and 22 and on Day 1 of Cycles 2 - 5

  3. Time to Maximum Observed Concentration (Tmax) of Duvelisib

    Time frame: Cycle 1 Day 1, 8, 15, and 22 and on Day 1 of Cycles 2 - 5

  4. Area Under the Plasma Concentration-time Curve (AUC) of Duvelisib

    Time frame: Cycle 1 Day 1, 8, 15, and 22 and on Day 1 of Cycles 2 - 5

Secondary outcomes

  1. Overall Response Rate

    Overall Response Rate is defined as the proportion of participants with a confirmed response of complete (CR) or partial response (PR) based on the revised International Working Group (IWG) criteria.

    Time frame: Throughout the study for approximately 2 years

  2. Overall Survival

    Overall survival is defined as the duration in weeks from the date of the first dose of study treatment until the date of death.

    Time frame: Throughout the study for approximately 2 years

  3. Progression Free Survival

    Progression free survival is defined as the time from the date of the first dose of study treatment to the first documentation of progressive disease (PD) or death due to any cause.

    Time frame: Throughout the study for approximately 2 years

07

Study locations

3 sites
  • Site Reference ID/Investigator# 141826
    Aichi, Japan
  • Site Reference ID/Investigator# 141595
    Fukuoka, Japan
  • Site Reference ID/Investigator# 141594
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Dec 2016, 13 months.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 13 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2015
First posted
Nov 6, 2015
StartActual
Nov 2015
Primary completionActual
Dec 2016
CompletionActual
Feb 2017
Last update
Feb 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02598570
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 6, 2015
Start date
Nov 2015
Primary completion
Dec 2016
Completion
Feb 2017
Last update
Feb 6, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion